| Organisation for Economic Co-operation and Development (OECD). Guidance Document on the Characterisation, Validation and Reporting of Physiologically Based Kinetic (PBK) Models for Regulatory Purposes [S]. Environment, Health and Safety, Environment Directorate, OECD, 2021 |
| Zhuang X M, Lu C. PBPK modeling and simulation in drug research and development [J]. Acta Pharmaceutica Sinica B, 2016, 6(5): 430-440 |
| Jia Q Y, He Q F, Yao L, et al. Utilization of physiologically based pharmacokinetic modeling in pharmacokinetic study of natural medicine: An overview [J]. Molecules, 2022, 27(24): 8670 |
| Zhao P, Zhang L, Grillo J A, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review [J]. Clinical Pharmacology and Therapeutics, 2011, 89(2): 259-267 |
| Gehring P J, Watanabe P G, Park C N. Resolution of dose-response toxicity data for chemicals requiring metabolic activation: Example—vinyl chloride [J]. Toxicology and Applied Pharmacology, 1978, 44(3): 581-591 |
| Andersen M E, Clewell H J 3rd, Gargas M L, et al. Physiologically based pharmacokinetics and the risk assessment process for methylene chloride [J]. Toxicology and Applied Pharmacology, 1987, 87(2): 185-205 |
| Gehring P J, Watanabe P G, Blau G E. Pharmacokinetic Studies in Evaluation of the Toxicological and Environmental Hazard of Chemicals [M]// New Concepts in Safety Evaluation, Advances in Modern Toxicology. Auburn, CA: Hemisphere Publishing Corp, 1976: 193-270 |
| Gehring P J, Watanabe P G, Young J D. The Relevance of Dose-dependent Pharmacokinetics in the Assessment of Carcinogenic Hazard of Chemicals [M]// Origins of Human Cancer. Vol 4. Book A: Incidence of Cancer in Humans. Long Island, NY: Cold Spring Harbor Laboratory, 1977: 187-203 |
| Lin Z, Li M, Wang Y, et al. Physiological parameter values for physiologically based pharmacokinetic models in food-producing animals. Part Ⅰ: Cattle and swine [J]. Journal of Veterinary Pharmacology and Therapeutics, 2020, 43(5): 385-420 |
| Najjar A, Punt A, Wambaugh J, et al. Towards best use and regulatory acceptance of generic physiologically based kinetic (PBK) models for in vitro-to-in vivo extrapolation (IVIVE) in chemical risk assessment [J]. Archives of Toxicology, 2022, 96(12): 3407-3419 |
| Breen M, Ring C L, Kreutz A, et al. High-throughput PBTK models for in vitro to in vivo extrapolation [J]. Expert Opinion on Drug Metabolism & Toxicology, 2021, 17(8): 903-921 |
| United States Environmental Protection Agency. Approaches for the application of physiologically based pharmacokinetic (PBPK) models and supporting data in risk assessment [R]. Washington D.C.: United States Environmental Protection Agency, 2006 |
| World Health Organization (WHO). Characterization and application of physiologically based pharmacokinetic models in risk assessment [R]. Geneva: WHO, 2010 |
| Yang D Y, Yang H, Shi M Y, et al. Advancing food safety risk assessment in China: Development of new approach methodologies (NAMs) [J]. Frontiers in Toxicology, 2023, 5: 1292373 |
| Sauerhoff M W, Braun W H, Blau G E, et al. The dose-dependent pharmacokinetic profile of 2,4,5-trichlorophenoxy acetic acid following intravenous administration to rats [J]. Toxicology and Applied Pharmacology, 1976, 36(3): 491-501 |
| McKenna M J, Zempel J A, Madrid E O, et al. The pharmacokinetics of vinylidene chloride in rats following inhalation exposure [J]. Toxicology and Applied Pharmacology, 1978, 45(2): 599-610 |
| McKenna M J, Zempel J A, Braun W H. The pharmacokinetics of inhaled methylene chloride in rats [J]. Toxicology and Applied Pharmacology, 1982, 65(1): 1-10 |
| Ramsey J C, Andersen M E. A physiologically based description of the inhalation pharmacokinetics of styrene in rats and humans [J]. Toxicology and Applied Pharmacology, 1984, 73(1): 159-175 |
| United States Environmental Protection Agency. Risk evaluation for N-methylpyrrolidone (2-pyrrolidinone, 1-methyl-) (NMP) [R]. Washington D.C.: United States Environmental Protection Agency, 2020 |
| European Food Safety Authority (EFSA). Outcome of a public consultation on the draft risk assessment of perfluoroalkyl substances in food [J]. EFSA Supporting Publications, 2020, 17(9): 1931E |
| Panel on Contaminants in the Food Chain (CONTAM), Schrenk D, Bignami M, et al. Update of the risk assessment of polybrominated diphenyl ethers (PBDEs) in food [J]. EFSA Journal, 2024, 22(1): e8497 |
| 中国生态环境部. 新化学物质环境管理登记指南[S]. 北京: 中国生态环境部, 2020 |
| European Chemicals Agency (ECHA). Guidance on Information Requirements and Chemical Safety Assessment, Chapter R.7c: Endpoint Specific Guidance [S]. Helsinki, Finland: European Chemicals Agency, 2023 |
| European Food Safety Authority (EFSA). Scientific opinion on good modelling practice in the context of mechanistic effect models for risk assessment of plant protection products [J]. EFSA Journal, 2014, 12(3): 3589 |
| Balhara A, Kale S, Singh S. Physiologically Based Pharmacokinetic (PBPK) Modelling [M]// Saharan V A. Computer Aided Pharmaceutics and Drug Delivery. Singapore: Springer, 2022: 255-284 |
| Upton R N, Foster D J, Abuhelwa A Y. An introduction to physiologically-based pharmacokinetic models [J]. Paediatric Anaesthesia, 2016, 26(11): 1036-1046 |
| Lin W, Chen Y, Unadkat J D, et al. Applications, challenges, and outlook for PBPK modeling and simulation: A regulatory, industrial and academic perspective [J]. Pharmaceutical Research, 2022, 39(8): 1701-1731 |
| Tsamandouras N, Rostami-Hodjegan A, Aarons L. Combining the 'bottom up’ and 'top down’ approaches in pharmacokinetic modelling: Fitting PBPK models to observed clinical data [J]. British Journal of Clinical Pharmacology, 2015, 79(1): 48-55 |
| Paini A, Tan Y M, Sachana M, et al. Gaining acceptance in next generation PBK modelling approaches for regulatory assessments: An OECD international effort [J]. Computational Toxicology, 2021, 18: 100163 |
| Jones H, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development [J]. CPT: Pharmacometrics & Systems Pharmacology, 2013, 2(8): e63 |
| Thompson M D, Beard D A. Development of appropriate equations for physiologically based pharmacokinetic modeling of permeability-limited and flow-limited transport [J]. Journal of Pharmacokinetics and Pharmacodynamics, 2011, 38(4): 405-421 |
| Ellison C A. Structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic (PBPK) model evaluation [J]. Regulatory Toxicology and Pharmacology, 2018, 99: 61-77 |
| Ellison C A, Wu S D. Application of structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic model development and evaluation [J]. Regulatory Toxicology and Pharmacology, 2020, 114: 104667 |
| McNally K, Cotton R, Loizou G D. A workflow for global sensitivity analysis of PBPK models [J]. Frontiers in Pharmacology, 2011, 2: 31 |
| Bois F Y, Ochoa J G D, Gajewska M, et al. Multiscale modelling approaches for assessing cosmetic ingredients safety [J]. Toxicology, 2017, 392: 130-139 |
| United States Food and Drug Administration. Physiologically Based Pharmacokinetic Analyses: Format and Content Guidance for Industry [S]. Silver Spring, Maryland: Food and Drug Administration Center for Drug Evaluation and Research (CDER), 2018 |
| European Medicines Agency. Guideline on the Reporting of Physiologically Based Pharmacokinetic (PBPK) Modelling and Simulation [S]. London: European Medicines Agency, 2018 |
| Bossier H, Chau J, Varewyck M, et al. Further development of a web-based open-source platform for toxicokinetic and toxicodynamic modelling: TKPlate 1.0 [J]. EFSA Supporting Publications, 2023, 20(11): 8437E |
| Raimondo S, Lilavois C, Nelson S A. Uncertainty analysis and updated user guidance for interspecies correlation estimation models and low toxicity compounds [J]. Integrated Environmental Assessment and Management, 2023. DOI: 10.1002/ieam.4884 |
| Madden J C, Pawar G, Cronin M T D, et al. In silico resources to assist in the development and evaluation of physiologically-based kinetic models [J]. Computational Toxicology, 2019, 11: 33-49 |
| Ahmad A, Pepin X, Aarons L, et al. IMI-Oral Biopharmaceutics Tools Project: Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies [J]. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 156: 50-63 |
| Wegner S H, Pinto C L, Ring C L, et al. High-throughput screening tools facilitate calculation of a combined exposure-bioactivity index for chemicals with endocrine activity [J]. Environment International, 2020, 137: 105470 |
| 张浩然, 杨道远, 欧曈, 等. 化学物危害特征描述中不确定系数制定的研究进展及其应用[J]. 生态毒理学报, 2024, 19(2): 1-11 Zhang H R, Yang D Y, Ou T, et al. Research advances and practical applications of uncertainty factors using in chemical hazard characterization [J]. Asian Journal of Ecotoxicology, 2024, 19(2): 1-11 (in Chinese) |
| Xie R L, Wang X D, Xu Y P, et al. In vitro to in vivo extrapolation for predicting human equivalent dose of phenolic endocrine disrupting chemicals: PBTK model development, biological pathways, outcomes and performance [J]. The Science of the Total Environment, 2023, 897: 165271 |
| Chen Q R, Chou W C, Lin Z M. Integration of toxicogenomics and physiologically based pharmacokinetic modeling in human health risk assessment of perfluorooctane sulfonate [J]. Environmental Science & Technology, 2022, 56(6): 3623-3633 |
| 李龙杰, 计佩影, 郑澳乐, 等. 人工智能结合生理药代动力学模型的研究进展[J]. 药学学报, 2024(5): 1-16 |